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Abstract
AIM: To investigate the safety/efficacy of Boceprevir-
based triple therapy in hepatitis C virus (HCV)-G1 
menopausal women who were historic relapsers, par-
tial-responders and null-responders. 
METHODS: In this single-assignment, unblinded 
study, we treated fifty-six menopausal women with 
HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure 
(7% null, 41% non-responder, and 52% relapser) with 
4 wk lead-in with PEG-IFNα2b/RBV followed by PEG-
IFNα2b/RBV+Boceprevir for 32 wk, with an additional 
12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-
positive by week 8. In previous null-responders, 44 wk 
of triple therapy was used. The primary objective of 
retreatment was to verify whether a sustained virologi-
cal response (SVR) (HCV RNA undetectable at 24 wk of 
follow-up) rate of at least 20% could be obtained. The 
secondary objective was the evaluation of the percent 
of patients with negative HCV RNA at week 4 (RVR), 8 
(RVR BOC), 12 (EVR), or at the end-of-treatment (ETR) 
that reached SVR. To assess the relationship between 
SVR and clinical and biochemical parameters, multiple 
logistic regression analysis was used.
RESULTS: After lead-in, only two patients had RVR; 
HCV-RNA was unchanged in all but 62% who had ≤ 
1 log10 decrease. After Boceprevir, HCV RNA became 
undetectable at week 8 in 32/56 (57.1%) and at week 
12 in 41/56 (73.2%). Of these, 53.8% and 52.0%, 
respectively, achieved SVR. Overall, SVR was obtained 
in 25/56 (44.6%). SVR was achieved in 55% previous 
relapsers vs. 41% non-responders (P  = 0.250), in 44% 
F0-F2 vs  54% F3-F4 (P = 0.488), and in 11/19 (57.9%) 
of patients with cirrhosis. At univariate analysis for 
baseline predictors of SVR, only previous response to 
antiviral therapy (OR = 2.662, 95%CI: 0.957-6.881, 
P  = 0.043), was related with SVR. When considering 
“on treatment” factors, 1 log10 HCV RNA decline at 
week 4 (3.733, 95%CI: 1.676-12.658, P  = 0.034) and 
achievement of RVR BOC (7.347, 95%CI: 2.156-25.035, 
P  = 0.001) were significantly related with the SVR, al-
though RVR BOC only (6.794, 95%CI: 1.596-21.644, P  
= 0.010) maintained significance at multivariate logis-
tic regression analysis. Anemia and neutropenia were 
managed with Erythropoietin and Filgrastim supple-
mentation, respectively. Only six patients discontinued 
therapy. 
CONCLUSION: Boceprevir obtained high SVR re-
sponse independent of previous response, RVR or 
baseline fibrosis or cirrhosis. RVR BOC was the only 
independent predictor of SVR.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: After menopause liver disease in hepatitis 
C virus-positive women becomes rapidly progressive, 
severe fibrosis develops, and response to antiviral 
therapy becomes very low. Re-treatment with standard 
dual therapy in previous failures of Peginterferon-α + 
Ribavirin (PEG-IFNα/RBV) treatments does not achieve 
more than 5%-10% sustained virological response 
(SVR). The addition of Boceprevir to PEG-IFNα/RBV in 
menopausal women with HCV-1 genotype infection, 
who had previously failed dual antiviral therapy, deter-
mined a striking improvement of SVR. More than 45% 
of women re-treated with triple therapy achieved SVR, 
with few side effects and good tolerability. Response af-
ter 4 wk of Boceprevir was the only independent factor 
predicting SVR.
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INTRODUCTION
Menopausal women with chronic hepatitis C are a group 
of  patients with remarkably distinctive characteristics 
when compared with women of  reproductive age or with 
males of  similar age[1,2]. Acceleration of  fibrosis in the 
past was attributed to several different factors: length of  
hepatitis C virus (HCV) infection[3], alcohol and smok-
ing[4], genetic characteristics of  patients[5]. Lately, the 
distinctive role of  menopause became apparent[2,6-8]. 
Soon after menopause liver disease becomes rapidly 
progressive and severe hepatic fibrosis develops[6-9], likely 
as a consequence of  the rapid increase of  inflamma-
tion as a direct consequence of  estrogen deprivation[8,10]. 
In menopausal HCV-positive women there is a strik-
ing up-regulation of  hepatic tumor necrosis factor-alfa 
(TNF-α), suppressor of  cytokine signaling-3 (SOCS3), 
interleukin-6 (IL-6), whose levels correlate with higher 
necro-inflammation and with faster progression of  liver 
fibrosis[9]. Not surprisingly, hormone replacement therapy 
(HRT) was shown to exert a positive effect slowing 
down fibrosis progression[6]. Even more disappointing is 
the fact that menopausal HCV-positive women become 
also resistant to conventional antiviral therapy with Peg-
Interferon-α + Ribavirin (PEG-IFNα/RBV): in our 
study of  women with HCV-1 genotype menopause was 
the only independent factor predicting failure of  dual an-
tiviral therapy[9]. This finding was confirmed in a prospec-
tive cohort study aimed to evaluate viral and host factors 
influencing antiviral therapy: genotype 1 females over 50 
years, had greatly reduced efficacy of  interferon-based 
therapy[11]. Furthermore, the evaluation of  our database 
for Hepatitis C showed that SVR rate after retreatment 
of  menopausal women with HCV-1 genotype was very 
low, ranging from 5% after retreatment with dual PEG-
IFNα/RBV in those having other unfavorable predictive 
factors like IL 28B (rs12979860) other than CC or high 
BMI[11-13] to 15% in those who had only menopause as 
risk factor (personal data). 
We decided, therefore, to perform an exploratory 
study using the results from the previous retreatment 
studies as historical control to evaluate whether the addi-
tion of  Boceprevir to standard PEG-IFN-α2b/RBV was 
able to increase the SVR rate in a difficult-to-treat cohort 
of  menopausal HCV genotype 1 women with a previous 
PEG-IFN-α/RBV failure.
MATERIALS AND METHODS
All patients gave written informed consent before start-
ing the study. The study was approved by the Institutional 
Review Board of  the Azienda Ospedaliero-Universitaria 
of  Modena (EudraCT 2011-002459-33) and by the ap-
propriate Institutional Review Boards of  the other Insti-
tutions and was conducted in accordance with provisions 
of  the Declaration of  Helsinki and Good Clinical Prac-
tice guidelines (Clinical Trials ID: NCT01457937).
Study patients
From December 2011 to June 2012 we screened 87 
consecutive menopausal women with HCV genotype 1 
infection and a documentation of  a failed prior course of  
PEG-IFN-α/RBV for at least 12 wk, followed up in the 
out patients clinics of  the Liver Units of  Modena, Turin, 
Palermo and Naples.
Inclusion criteria included patients with relapse (un-
detectable HCV RNA level at the end of  treatment, 
without subsequent attainment of  a sustained virological 
response), prior partial-response (defined as decrease of  
HCV-RNA ≥ 2 log10 by week 12 of  prior therapy but 
with detectable HCV-RNA throughout the course of  
therapy), or null-response (decrease of  HCV-RNA ≤ 2 
log10 by week 12 of  prior therapy).
A liver biopsy within the last 2 years with histology 
consistent with chronic hepatitis C (CHC) and no other 
etiology was required. In subjects with bridging fibrosis 
or cirrhosis, an ultrasound within 6 mo of  the Screening 
Visit (or between Screening and Day 1) with no findings 
suspect for hepatocellular carcinoma (HCC) was manda-
tory.
Exclusion criteria included co-infection with the hu-
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man immunodeficiency virus (HIV) or hepatitis B virus 
(HBsAg positive), treatment with any investigational drug 
within 30 d of  the randomization visit in this study, evi-
dence of  decompensated liver disease including history 
or presence of  clinical ascites, bleeding varices, or hepatic 
encephalopathy, diabetic and/or hypertensive subjects 
with clinically significant ocular examination findings 
(like retinopathy, cotton wool spots, optic nerve disorder, 
retinal hemorrhage, or any other clinically significant ab-
normality), pre-existing psychiatric conditions, clinical di-
agnosis of  substance abuse of  the specified drugs within 
the specified timeframes, any known pre-existing medical 
condition that could interfere with the subject’s participa-
tion in and completion of  the study, evidence of  active or 
suspected malignancy, or a history of  malignancy, within 
the last 5 years (except adequately treated carcinoma in 
situ and basal cell carcinoma of  the skin). Further exclu-
sion criteria included protocol-specified hematologic, 
biochemical, and serologic criteria: hemoglobin < 12 g/
dL; neutrophils < 1500/mm3; platelets < 100000/mm3, 
direct bilirubin >1.5 × upper limit of  normal (ULN), 
serum albumin < lower limit of  normal (LLN), thyroid-
stimulating hormone (TSH) > 1.2 × ULN or < 0.8 × 
LLN of  laboratory, serum creatinine > ULN of  the 
laboratory reference, protocol-specified serum glucose 
concentrations, prothrombin time/partial thromboplastin 
time (PT/PTT) values > 10% above laboratory reference 
range, anti-nuclear antibodies > 1:320.
Study design
In this single-assignment, unblinded study we treated 
menopausal women with previous treatment failure to a 
prior course of  PEG-IFN/RBV. The primary objective 
of  retreatment was to verify whether a sustained virologi-
cal response (SVR) (HCV RNA undetectable at 24 wk of  
follow-up) rate of  at least 20% could be achieved with 
Boceprevir in menopausal women with chronic HCV 
genotype 1 with a previous failure of  PEG IFN/Ribavi-
rin. Secondary objective of  this study was the evaluation 
of  the percent of  patients with negative HCV RNA at 
week 4 (rapid virological response, RVR), 8 (rapid viro-
logical response after BOC addition, RVR BOC), 12 (early 
virological response, EVR), or at the end-of-treatment 
(ETR) that reached SVR. 
All patients received 4-wk lead-in with with PEG-
IFN-α-2b at 1.5 mg/kg subcutaneously weekly, in combi-
nation with weight-based oral RBV at a total dose of  800 
to 1400 mg per day according to body weight. In relapse 
and partial responder patients after 4 wk of  lead-in, all 
patients received 32 wk of  BOC 800 mg administered 
orally three times a day, in combination with PEG-IFN 
and RBV. These patients then received an additional 12 
wk of  PR only if  HCV-RNA was positive by week 8 yet. 
In previous null-responders, after the lead-in phase, triple 
therapy with PEG-IFN/Ribavirin and Boceprevir was 
continued until week 48. All drugs were self-administered 
by the patients.
In all patients, if  HCV RNA was detectable at week 
12, treatment was stopped. 
IL28 genotyping
IL28B rs12979860 genotype was tested as already de-
scribed[13]. 
Safety assessment
Adverse events (AEs) were graded according to WHO 
grading system. The safety analyses included all subjects 
who receive at least one dose of  study medication. Non 
severe hematological adverse events were managed by 
pharmacological dose reduction. In case of  neutrophil 
count < 0.75 × 109/L, granulocyte colony stimulating 
factor (GCS-F) was also used. In case of  hemoglobin 
decrease < 10 g/dL, Ribavirin dose was reduced and/or 
erythropoietin administered. 
Subjects having AEs were monitored with appropriate 
clinical assessments and laboratory tests, as determined 
by the investigator. 
Statistical analysis
Analysis regarding the primary end-point included all 
patients who had received at least one dose of  any study 
medication (intention-to-treat analysis). Our primary end-
point was attainment of  sustained virological response, 
defined as undetectable circulating HCV RNA at week 24 
of  follow-up. Secondary end point was the identification 
of  independent baseline and on-treatment SVR predictors. 
To calculate sample size, we estimated to obtain at 
least a 20% increase in SVR vs historical controls with the 
same characteristic. Thus, with 80% power and a type 1 
error set to 0.05, 49 subjects were required. A 15% excess 
of  inclusions was allowed in order to compensate for 
withdrawals.
Dichotomous or continuous variables were compared 
with the Fisher exact test with mid-p correction or the 
nonparametric Mann-Whitney rank-sum test, respectively.
To assess the relationship between SVR and clini-
cal and biochemical parameters, two multiple logistic 
regression models were used; the first assessed baseline 
variables only and the second assessed both baseline and 
on-treatment parameters. In the statistical model, the de-
pendent variable was coded as 1 (present) vs 0 (absent). In 
all analyses, partial and null responders were considered 
together and referred to as non-responders. Variables as-
sociated with the dependent variable in univariate analy-
ses (probability threshold, P < 0.10) were included in the 
multivariate regression model. The PASW Statistics 20 
program (SPSS, Inc, Chicago, IL) was used for the analy-
sis. 
RESULTS
Study patients
A total of  87 menopausal women with chronic Hepatitis 
C, genotype 1, with previous treatment failure to standard 
antiviral therapy, were evaluated (Figure 1). Baseline char-
acteristics of  the 56 enrolled patients are shown in Table 
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ability at week 12; 3/14 (21%) for viral breakthrough]. All 
experienced a virological relapse. 
The rate of  sustained virological response among 
patients with prior relapse or non-response was 55% 
and 41% respectively (P = 0.250). No significant correla-
tion was present between SVR and high viral load (HCV 
RNA > 800.000 IU/mL: P = 0.597) or IL28 status (P 
= 0.333). Patients with IFN sensitivity had significantly 
higher SVR rates compared patients with IFN insensitiv-
ity (57.1% vs 26.3%, P = 0.030). Level of  fibrosis did not 
negatively influence the SVR rate, which occurred in 44% 
of  women with F0-F2 vs 54% of  those with F3-F4 fibro-
sis (P = 0.488) nor was the presence of  cirrhosis (presence 
of  cirrhosis vs. absence: P = 0.485). Figure 2 depicts SVR 
rates according to the pattern of  prior response, severity 
of  fibrosis and baseline viral load.
At univariate analysis for baseline predictors of  SVR, 
none of  the clinical and biochemical parameters but 
previous response to antiviral therapy (OR = 2.662, 
95%CI: 0.957-6.881, P = 0.043) was related with SVR. 
When taking into consideration also “on treatment” fac-
tors, 1 log10 HCV RNA decline at week 4 (3.733, 95%CI: 
1.676-12.658, P = 0.034) and achievement of  RVR BOC 
(7.347, 95%CI: 2.156-25.035, P = 0.001) were signifi-
cantly related with SVR, although RVR BOC only (6.794, 
95%CI: 1.596-21.644, P = 0.010) maintained significance 
at multivariate logistic regression analysis (Table 2). 
1. Thirty-eight women were from Northern Italy while 
18 were from Southern Italy. There were no significant 
differences between them regarding previous response 
to antiviral therapy, percentage of  patients with cirrhosis, 
IL28B genotype, basal BMI, duration of  menopause, 
basal viral load. All patients completed follow up and 
were included in the analysis.
Mean age was 56.8 ± 6.1 years; mean menopausal 
duration was 11.4 ± 6.1 years (median 12.5 years). Mean 
BMI was 26.2 ± 4.0 (median 24.8). Four patients (7.1%) 
were previous null responders, 23 (41.1%) partial-re-
sponders and 29 (51.8%) relapsers. According to Metavir 
fibrosis score, 30/56 (54.0%) women had a score of  1 or 
2, while 26/56 (46.0%) had a score of  3 or 4; of  these, 
21 (37.5%) had cirrhosis. Approximately 60% of  patients 
had a high viral load (an HCV RNA level > 800000 IU 
per milliliter). Genotype 1b infection was predominant 
(52/56, 92.9%). IL28B rs12979860 genotype was avail-
able for 43 patients (9 CC, 26 TC, and 8 TT).
Efficacy
In the entire population, SVR was obtained in 25/56 
(44.6%) patients. There was no significant difference 
between women of  Northern and Southern origin in the 
SVR rate (44.7% vs 44.4%, respectively, P = 0.964). 
After 4 wk of  lead-in, none but two patients achieved 
RVR, while the HCV RNA drop of  at least 1 log10 from 
baseline (IFN sensitivity) was obtained in 62% of  pa-
tients. After Boceprevir addition, RVR BOC, EVR and 
ETR were obtained in 32/56 (57.1%), 41/56 (73.2%), 
and 42 (75.0%) respectively. Of  these, 53.8%, 52.0%, and 
52.0%, respectively, achieved SVR. 
Fourteen patients (25.0%) stopped therapy [6/14 
(43%) for intolerance, 5/14 (36%) for HCV RNA detect-
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Patients diagnosed with HCV+ CAH 
(n  = 87)
Patients allocated to 
intervention 
 (n  = 56)
Excluded n  = 31
   10 denied consent
   9 low platelets count
   8 co-morbidities
   4 co-infections
Lost to follow up (n  = 0)
Discontinued intervention for AEs (n  = 6)
HCV RNA detectable at week 12 (n  = 5)
Breakthrough (n  = 3)
Analyzed (n  = 56)
Figure 1  Trend statement flow diagram. HCV: Hepatitis C virus; AE: Adverse 
event.
Table 1  Demographic characteristics of the 56 patients at 
enrollment
Variables
Mean age, mean ± SD (yr) 56.8 ± 6.1
Mean age at menopause, mean ± SD (yr) 49.3 ± 4.3
Time from menopause, mean ± SD (yr) 11.4 ± 6.1
Previous response n (%) 　
   Relapse 29 (51.8)
   Non response 23 (41.1)
   Null response 4 (7.1)
Grading 5.1 ± 2.4
Staging 2.3 ± 1.3
Cirrhosis 21 (37.5)
Stiffness (kPa) 10.3 ± 7.1
BMI, mean ± SD 26.2 ± 4.0
Blood glucose, mean ± SD (mg/dL) 101 ± 22
Insulin_base (U/mL)   9.9 ± 7.9
HOMA score   2.5 ± 1.5
Blood Iron (mg/dL) 128 ± 87
Hb (g%) 13.0 ± 2.2
WBC (K/mL)   4.9 ± 1.4
Neutrophils (K/mL)   2.5 ± 0.9
Platelets (103/mm3) 206 ± 78
BUN (mg/dL)   36 ± 11
Creatinine (mg/dL)   0.7 ± 0.1
AST (IU/L)   58 ± 24
ALT (IU/L)   66 ± 27
ALP (IU/L)   95 ± 28
Gamma-GT (IU/L)   45 ± 15
HCV RNA (IU/mL, 103)   1.440 ± 1.178
BMI: Body mass index; ALT: Alanine aminotransferase; WBC: White blood 
cell; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase.
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Safety
Anaemia and neutropenia were managed with Erythro-
poietin and Granulokine supplementation, respectively: 
only six patients discontinued therapy.
The treatment was well tolerated, with low rates of  
severe adverse events. Fatigue and nausea were the most 
common adverse events. Hemoglobin levels decreased 
significantly at all-time points, without requiring the in-
troduction of  erythropoietin before week 6 (i.e., 2 wk 
following the addition of  boceprevir). Conversely, the 
neutrophil count reduction required Granulokine supple-
mentation already at week 2. Anemia was successfully 
managed with erythropoietin supplementation, as neu-
tropenia with Granulokine supplementation. The supple-
mentation of  both Erythropoietin and Granulokine was 
necessary to preserve the full treatment doses. None of  
the patients experienced skin problems; dysgeusia was 
frequent, but no patient discontinued therapy due to this 
event (Table 3).
DISCUSSION
In this study on a cohort of  difficult-to-treat genotype 1 
CHC patients (menopausal females, failure to a previous 
course of  PEG-IFN/RBV, high prevalence of  F3-F4 
fibrosis) we showed that retreatment with a BOC-based 
TT regimen leads to SVR in about 45% of  cases, RVR 
BOC being the only independent predictor of  SVR.
The achievement of  SVR in a great proportion of  
patients gives BOC-based therapy a relevant option for 
this group of  difficult-to-treat patients, where a deferral 
strategy towards IFN-free regimens should be carefully 
evaluated due to the rapid progression of  the liver dis-
eases related to the menopausal status.
Menopausal women with chronic HCV genotype 1 
infection are patients experiencing an utmost resistance 
to antiviral therapy with PEG-IFN-α and Ribavirin oc-
curring at and soon after the onset of  menopause[9]. This 
issue could be probably further amplified in patients who 
failed a previous treatment with PEG-IFN and Ribavirin. 
In this clinical context several studies, not stratified for 
gender and menopausal status, were not able to obtain 
more than a 3%-21% SVR despite employing PEG-
IFN/RBV-based treatment schedules with higher PEG-
IFN-α dosages or longer period of  treatment than rou-
tinely used[14-18]. As in all the above studies, our cohort 
of  menopausal patients with a previous failure to dual 
antiviral therapy exhibited a marked lack of  sensitivity 
toward interferon, i.e., none but two patients achieved 
RVR after the 4-wk lead-in, and a substantial proportion 
displayed less than 1 log decline of  viral load. Despite 
the this occurrence, the addition of  Boceprevir deter-
mined a striking effect: viral load became undetectable 
in almost 60% of  patients after 4 wk and in more than 
70% at week 12, and finally SVR was obtained in 45% of  
women. The SVR we obtained is slightly lower than that 
reported in the study by Bacon et al[17] who, with a similar 
treatment regimen, obtained a 59% and 66% depending 
on the treatment schedule. It should, however, be un-
derlined that the population undergoing treatment in the 
Bacon study was characterized by much more favorable 
characteristics in term of  response to antiviral therapy 
like younger age and less advanced disease than ours. A 
recent paper by Vierling et al[19] reported higher SVR rates 
with BOC re-treatment. Enrolled patients belonged to 
control arm of  4 Boceprevir studies (SPRINT-2, RE-
SPOND-2, SPRINT-1, or Protocol 05685)[17,20-22] and 
had not achieved SVR. They were enrolled soon (< 2 
wk) after a failed PEG-IFN-α/RBV course at least 12 
wk that however, in about 40% of  patients, had lasted 48 
wk. This makes the results scarcely comparable with the 
other re-treatment studies and ours as the patients were 
exposed in a restricted period of  time to PEG-IFN-α/
RBV for more than double the usual duration of  therapy. 
The results reported by Flamm et al[23] of  retreatment of  
patients previously treated with chronic hepatitis C geno-
type 1 infection are consistent with ours: subjects who 
had had poor response to interferon therapy (< 1 log10 
decline in HCV RNA at week 4), had only a 39% SVR. 
Interestingly, none of  the patients with less than 1 log de-
cline had SVR when retreated with dual PEG-IFN/RBV. 
As a general remark, in none of  the previously cited 
retreatment studies was the stratification by menopausal 
status available.
Another relevant finding of  our study lies in the iden-
tification of  RVR BOC as the only independent predictor 
of  SVR. This result raises attention for relevant practi-
cal issues in the management of  this difficult-to-treat 
group of  patients, when RVR BOC occurs, the pattern 
of  previous failure to dual therapy does not significantly 
affect the likelihood of  SVR to BOC-based TT. Second, 
although 1 log10 decline of  viral load after 4 wk of  dual 
therapy identified patients at higher SVR likelihood, it 
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cording to prior response to Peginterferon-α + Ribavirin treatment, level 
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was not confirmed as independently associated with SVR 
at multivariate analysis. Third, none of  the other factors 
that are traditionally associated with achievement of  a 
sustained virological response (i.e., low viral load at base-
line, absence of  fibrosis or cirrhosis, IL 28B genotype, 
> 1 log10 decrease in HCV RNA)[24] was independently 
related with SVR. It is of  note that the relevance of  RVR 
BOC as predictor of  SVR has been identified in other 
studies of  difficult-to-treat population like patients with 
cirrhosis[25,26].
The main limitation of  this study lies in the poten-
tially limited external validity of  the results for different 
populations and settings. Our study included a cohort of  
Italian patients enrolled at tertiary care centers, who may 
be different from general population, in terms of  both 
metabolic features and severity of  liver disease, limiting 
the broad application of  the results. 
In conclusion, Boceprevir addition to standard PEG-
IFN-α/RBV therapy was effective in achieving SVR in 
about 50% of  menopausal women with chronic hepatitis 
C, genotype 1, who had failed SVR with prior PEG-
IFN-α/RBV treatment. Most importantly, Boceprevir-
based triple therapy success rate was not influenced by 
pattern of  previous response to DT or by the severity of  
liver fibrosis while RVR BOC was the only independent 
predictor of  SVR. This opens a relevant possibility for 
patients who are at high risk of  a rapid progression to-
ward cirrhosis and/or decompensation.
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Table 2  Univariate and multivariate analysis for factors predicting sustained virological response
Variables Univariate analysis OR (95% CI) P  value Multivariate analysis OR (95% CI) P  value
Age (yr) 1.006 (0.916-1.105) 0.900
Age at menopause 1.150 (0.931-1.450) 0.195
Previous response 2.662 (0.957-6.881) 0.043 2.927 (0.931-9.206) 0.066
Histological grading 0.894 (0.605-1.322) 0.576
Histological staging 0.982 (0.586-1.645) 0.946
Fibrosis 1.667 (0.528-5.265) 0.384
Liver stiffness 0.986 (0.895-1.086) 0.774
Cirrhosis 1.111 (0.155-7.974) 0.917
BMI 1.000 (0.825-1.212) 1.000
HCV RNA > 800.000 IU/mL 0.519 (0.120-2.248) 0.381
RVR   1.200 (0.070-20.429)  0.900
1 log decline at week 4   3.733 (1.676-12.658) 0.034 0.961(0.194-4.757)  0.961
RVR BOC   7.347 (2.156-25.035)  0.001   6.794 (1.596-21.644) 0.010
ALT (IU/mL) 0.996 (0.977-1.014) 0.645
Platelets (× 103/mm3) 1.000 (1.000-1.000) 0.165
HOMA 0.907 (0.533-1.544) 0.719
Table 3  Adverse events  n  (%)
Event 
Death, n 0
Drug Discontinuation due to AE    6 (10)
Dose Modification due to AE   8 (14)  
Any life-threatening adverse event, n 0
Any serious adverse event 2 (4)
Hematologic event
   Reduced neutrophil count  
      < 750 per mm3 
      < 500 per mm3
14 (25)
  8 (15)
Mean change in hemoglobin from baseline (g/dL)
   At wk 12 -1.2
   At wk 24 -2.2
   At wk 48 -3.3
Erythropoietin use 20 (35)
Transfusion   1 (1.8)
Common adverse event
   Nausea 24 (43)
   Anemia 23 (41)
   Dysgeusia 20 (36)
   Fatigue 18 (32)
   Rash   6 (11)
BMI: Body mass index; HCV: Hepatitis C virus; ALT: Alanine aminotransferase.
AE: Adverse event.
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